InflaRx (IFRX) to Release Earnings on Friday

InflaRx (NASDAQ:IFRX) is expected to post its Q3 2025 results before the market opens on Friday, November 14th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $0.03 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 10, 2025 at 12:00 AM ET.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.24). The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.02 million. On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

InflaRx Price Performance

InflaRx stock opened at $1.20 on Friday. InflaRx has a 12 month low of $0.71 and a 12 month high of $2.82. The company has a fifty day moving average price of $1.39 and a two-hundred day moving average price of $1.18. The company has a market cap of $80.56 million, a PE ratio of -1.50 and a beta of 1.38.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on IFRX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of InflaRx in a research report on Tuesday, October 14th. HC Wainwright assumed coverage on InflaRx in a report on Tuesday, September 2nd. They set a “buy” rating and a $6.00 target price for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $6.20.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Woodline Partners LP acquired a new stake in InflaRx in the first quarter worth about $766,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of InflaRx during the 2nd quarter worth about $262,000. Finally, Cubist Systematic Strategies LLC lifted its stake in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after acquiring an additional 7,616 shares during the period. 42.39% of the stock is owned by institutional investors and hedge funds.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.